Clinical Trial Update: Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a triplet regimen of golidocitinib with azacitidine and chidamide in peripheral T-cell lymphoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Chidamide (chidamide)
• Golidocitinib (golidocitinib)

Snippet

Sponsor: Ruijin Hospital | Conditions: Peripheral T-Cell Lymphoma, Not Classified | Phase 2 | Status: NOT_YET_RECRUITING